CRIS Curis Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CRIS

Price (delayed)

$1.87

Market cap

$3.64M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$16.2

Enterprise value

-$10.02M

?
Relative Growth: Rel. Growth: 17
Relative Strength: Rel. Strength: 0
Relative Valuation: Rel. Valuation: 37
Relative Profitability: Rel. Profitability: 31

Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 and FLT3 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase ...

Highlights
The equity has soared by 133% from the previous quarter
CRIS's debt is down by 49% YoY and by 17% from the previous quarter
The net income has dropped by 179% since the previous quarter but it is up by 50% year-on-year
CRIS's quick ratio has surged by 178% since the previous quarter but it is down by 11% year-on-year
The revenue has declined by 37% year-on-year and by 25% since the previous quarter
The gross profit has contracted by 37% YoY and by 25% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.curis.com
Peers: EXEL EBS CLDX PFE

Key stats

What are the main financial stats of CRIS

CRIS stock price

How has the Curis stock price performed over time
Intraday
11.98%
1 week
-57.6%
1 month
-60.63%
1 year
-94.56%
YTD
-90.53%
QTD
-82.09%

Financial performance

How have Curis's revenue and profit performed over time
Revenue
$7.06M
Gross profit
$7.03M
Operating income
-$7.08M
Net income
-$21.17M
Gross margin
99.6%
Net margin
-299.7%
The net income has dropped by 179% since the previous quarter but it is up by 50% year-on-year
Curis's operating income has surged by 83% YoY but it has decreased by 24% QoQ
CRIS's operating margin has soared by 73% year-on-year but it has dropped by 66% since the previous quarter
The revenue has declined by 37% year-on-year and by 25% since the previous quarter

Price vs fundamentals

How does CRIS's price correlate with its fundamentals

Growth

What is Curis's growth rate over time

Valuation

What is Curis stock price valuation
P/E
N/A
P/B
0.29
P/S
0.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-1.42
Curis's EPS has surged by 87% YoY but it has decreased by 40% QoQ
The equity has soared by 133% from the previous quarter
CRIS's price to sales (P/S) is 98% lower than its 5-year quarterly average of 10.4 and 86% lower than its last 4 quarters average of 1.9
The revenue has declined by 37% year-on-year and by 25% since the previous quarter

Efficiency

How efficient is Curis business performance
Curis's return on sales has increased by 20% YoY
The company's return on assets rose by 18% YoY

Dividends

What is CRIS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRIS.

Financial health

How did Curis financials performed over time
The company's total assets is 75% higher than its total liabilities
CRIS's quick ratio has surged by 178% since the previous quarter but it is down by 11% year-on-year
The current ratio has surged by 127% since the previous quarter but it has declined by 10% year-on-year
CRIS's debt is 89% less than its equity
The equity has soared by 133% from the previous quarter
The debt to equity has soared by 128% YoY but it has shrunk by 63% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.